CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
1.060
+0.072 (7.27%)
Apr 6, 2026, 4:00 PM EDT - Market closed

CytoMed Therapeutics Balance Sheet

Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2.14.9791.582.51
Cash & Short-Term Investments
2.14.9791.582.51
Cash Growth
-57.84%-44.74%469.41%-37.13%183.84%
Accounts Receivable
1.571.031.1--
Other Receivables
---0.910.77
Total Trade Receivables
1.571.031.10.910.77
Total Current Assets
3.66610.12.493.28
Net Property, Plant & Equipment
3.693.252.062.472.5
Other Intangible Assets
0.120.090.010.020.03
Long-Term Investments
0.020.220.20.240.27
Other Long-Term Assets
0.490.5---
Total Assets
7.9810.0712.375.236.08
Accounts Payable
0.440.440.520.420.22
Short-Term Debt
---3.42.31
Current Portion of Long-Term Debt
0.040.040.030.330.39
Current Portion of Leases
0.020.010.010.010.01
Unearned Revenue
0.180.110.0100.01
Other Current Liabilities
0.030.010.150-
Total Current Liabilities
0.710.610.724.172.94
Long-Term Debt
0.370.390.410.470.54
Long-Term Leases
0.050.02-0.010.02
Total Long-Term Liabilities
0.420.420.410.480.55
Total Liabilities
1.131.021.124.643.49
Common Stock
24.6623.7923.728.916.55
Additional Paid-in Capital
0.640.070.07-1.14
Accumulated Other Comprehensive Income
0.08-0.05-0.22-0.13-0.03
Retained Earnings
-18.83-14.85-12.33-8.2-5.07
Total Common Shareholders' Equity
6.548.9711.250.592.59
Minority Interest
0.310.08-0-0-0
Shareholders' Equity
6.859.0411.240.592.59
Total Liabilities & Equity
7.9810.0712.375.236.08
Total Debt
0.480.460.454.223.26
Net Cash (Debt)
1.614.518.55-2.64-0.75
Net Cash Growth
-64.21%-47.27%---
Net Cash Per Share
0.140.390.80-0.33-0.09
Book Value
6.548.9711.250.592.59
Book Value Per Share
0.560.781.060.070.33
Tangible Book Value
6.428.8711.230.572.56
Tangible Book Value Per Share
0.550.771.060.070.32
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q